- Home
- IMNM vs PDT Comparison
IMNM vs PDT Comparison
Compare IMNM & PDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- PDT
- Stock Information
- Founded
- IMNM 2006
- PDT 1989
- Country
- IMNM United States
- PDT United States
- Employees
- IMNM N/A
- PDT N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- PDT Finance Companies
- Sector
- IMNM Health Care
- PDT Finance
- Exchange
- IMNM Nasdaq
- PDT Nasdaq
- Market Cap
- IMNM 748.3M
- PDT 627.1M
- IPO Year
- IMNM 2020
- PDT N/A
- Fundamental
- Price
- IMNM $9.06
- PDT $13.16
- Analyst Decision
- IMNM Strong Buy
- PDT
- Analyst Count
- IMNM 5
- PDT 0
- Target Price
- IMNM $26.40
- PDT N/A
- AVG Volume (30 Days)
- IMNM 973.9K
- PDT 145.6K
- Earning Date
- IMNM 05-12-2025
- PDT 01-01-0001
- Dividend Yield
- IMNM N/A
- PDT 8.88%
- EPS Growth
- IMNM N/A
- PDT N/A
- EPS
- IMNM N/A
- PDT N/A
- Revenue
- IMNM $10,938,000.00
- PDT N/A
- Revenue This Year
- IMNM N/A
- PDT N/A
- Revenue Next Year
- IMNM $542.22
- PDT N/A
- P/E Ratio
- IMNM N/A
- PDT N/A
- Revenue Growth
- IMNM N/A
- PDT N/A
- 52 Week Low
- IMNM $5.15
- PDT $8.77
- 52 Week High
- IMNM $16.81
- PDT $13.05
- Technical
- Relative Strength Index (RSI)
- IMNM 61.94
- PDT 65.48
- Support Level
- IMNM $8.50
- PDT $12.65
- Resistance Level
- IMNM $9.04
- PDT $12.94
- Average True Range (ATR)
- IMNM 0.54
- PDT 0.18
- MACD
- IMNM 0.09
- PDT 0.05
- Stochastic Oscillator
- IMNM 90.18
- PDT 96.10
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
About PDT John Hancock Premium Dividend Fund
John Hancock Premium Div Fund is a United States-based closed-end management investment company. It seeks to provide a high current income consistent with modest growth of capital. The fund will pursue its objective by investing in a diversified portfolio comprised of dividend-paying preferred securities and common equity securities. The portfolio composition of the fund consists of preferred securities, common stocks, corporate bonds, capital preferred securities, and short-term investments.